If you or your loved one has early stage Alzheimer's disease (AD), you may be eligible for this study. This study is evaluating an investigational drug called BPN14770 as a possible treatment for patients with early stage AD.
You or your loved one may already be taking a cholinesterase inhibitor such as Aricept (donepezil), but there is a need to find drugs that may work in other ways.
To be eligible for this study, you must be 55 to 85 years of age and diagnosed with early stage AD. You must be receiving Aricept (donepezil) or another cholinesterase inhibitor for the treatment of AD for at least 2 months.